54 stories found
Pharmaceutical giant Eli Lilly is making a major strategic investment in autoimmune treatments, betting heavily on pipeline development despite potential regulatory hurdles and competitive market risks.
Financial analysts question whether the GLP-1 weight-loss medication sector is truly a winner-take-all duopoly or if broader market dynamics favor multiple competitors.
Financial commentator Jim Cramer has identified pharmaceutical giants like Johnson & Johnson (JNJ) and Eli Lilly (LLY) as strong investment opportunities. He highlights these companies as innovative plays outside the traditional technology sector.
An analysis delves into the extent of investment in Eli Lilly (LLY), examining the factors driving its market valuation and investor interest. The report assesses the company's current position and future prospects.
Eli Lilly (LLY) is being discussed as one of billionaire investor Cliff Asness’s best healthcare stock picks, highlighting its potential in the market.
Eli Lilly (LLY) has announced the acquisition of Centessa Pharmaceuticals, aiming to further develop Orexin Receptor 2 Agonists for its pharmaceutical pipeline.
Eli Lilly (LLY) is taking steps to enforce compliance with 340B claims data reporting requirements.
Eli Lilly (LLY) is highlighted as one of the top 10 safe stocks recommended for long-term investment in 2026.
Eli Lilly (LLY) has released new results from its late-stage clinical trials for a weight loss treatment, potentially impacting the market for obesity drugs.
Wolfe Research suggests that the market's reaction to Eli Lilly's (LLY) Foundayo report appears to be excessive, indicating a potential overcorrection in the stock price.
A range of companies, including Exponent, Trupanion, Illumina, and Roblox, have announced their financial forecasts for 2026, detailing projected revenues, EPS, and EBITDA margins. Several other companies also reported their latest quarterly or fiscal year results.
Eli Lilly and Company (LLY) experienced a stock decline in the first quarter, even as the pharmaceutical giant reported strong overall results.
Eli Lilly (LLY) has been identified as one of the eight best beginner stocks to buy, according to a recent market analysis.
Jim Cramer has offered his perspective on whether Eli Lilly (LLY) stands out as the best healthcare stock for investors to consider.
Eli Lilly is reportedly planning to invest $3 billion in China over the next ten years, as reported by Reuters, signaling a significant expansion in the region.
Barclays has begun its coverage of Eli Lilly (LLY), expressing a positive outlook due to the company's robust standing in the obesity treatment market.
Financial analysis explores whether the strategic collaboration between biotech firm OmniAb and pharmaceutical giant Eli Lilly could significantly drive growth and innovation for OmniAb.
Bristol-Myers Squibb (BMY) has committed $2.3 billion to investments in Texas, while Eli Lilly (LLY) has achieved significant success in the United Kingdom market.
Eli Lilly (LLY) announced significant growth in its latest financial report and subsequently raised its future outlook, indicating strong performance.
Eli Lilly (LLY) stock is demonstrating strong momentum, but analysts are questioning its current valuation and price point.
Eli Lilly (LLY) and BioArctic AB have announced a new research and collaboration agreement, aiming to advance scientific discoveries and develop new treatments.
Hedge funds are reportedly considering Eli Lilly (LLY) as one of the most profitable blue-chip stocks to buy.
Eli Lilly announced positive results from its Phase 1b study of Verve-102, a new investigational drug, indicating promising progress in its clinical development.
Eli Lilly (LLY) has reported positive Phase 3 clinical trial results for its investigational obesity treatment, Retatrutide, marking a significant development in the pharmaceutical company's pipeline.
An analyst has raised Eli Lilly (LLY) price target by $52 following the company's Q1 report.
Analysts have highlighted Eli Lilly and Company (LLY) as one of the best drug stocks to consider for investment. The report outlines the reasons behind this positive assessment.
Analysts are assessing the investment potential of several healthcare and pharmaceutical companies, including Eli Lilly, IGC Pharma, and 60 Degrees Pharmaceuticals. They are providing insights and recommendations for investors considering these stocks.
Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has requested additional clinical data regarding its experimental obesity pill, potentially delaying its approval.
Eli Lilly (LLY) has received FDA approval for its new weight management pill, Foundayo, marking a significant development in the treatment of obesity.
Eli Lilly (LLY) has seen gains driven by the strong performance and growth of its GLP-1 franchises drugs.
Bank of America analysts anticipate a limited impact on Eli Lilly's franchise despite Novo's recent GLP-1 price update.
Eli Lilly (LLY) is reportedly expanding its pharmaceutical pipeline through a new agreement involving Clazakizumab, as reported by Reuters.
Eli Lilly filed a lawsuit targeting six pharmaceutical companies for allegedly marketing unapproved weight-loss drugs, positioning itself to maintain dominance in the competitive GLP-1 market alongside rival Novo Nordisk.
Investors are watching Eli Lilly (LLY) stock for a potential stock split.
An analysis questions whether Eli Lilly maintains its leadership in the $150 billion obesity drug market.
Claude AI has reportedly expressed disagreement with President Trump concerning Eli Lilly (LLY) stock.
Eli Lilly (LLY) announced positive Phase 3 results for its Jaypirca combination therapy in patients with relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
CVS will restore coverage for Eli Lilly's weight-loss drug Zepbound and add it to its drug plans. This decision comes after Eli Lilly reportedly slashed the price of the medication.
Eli Lilly (LLY) is experiencing robust growth, primarily driven by the momentum of its drug Mounjaro and increasing demand for GLP-1 medications, leading Barclays to maintain a bullish outlook on the company.
An analysis highlights Eli Lilly (LLY) as one of the best stocks to consider buying for investment over the next 15 years.
Truist has reaffirmed its 'Buy' rating for Eli Lilly (LLY) following the success of a recent trial. The positive trial results are expected to bolster investor confidence in the pharmaceutical giant.
Guggenheim has increased its price target for Eli Lilly (LLY), attributing the adjustment to the pharmaceutical company's recent series of acquisition deals.
An article advises investors not to be concerned about the prospects of Eli Lilly (LLY) and Company's Foundayo treatment, implying positive outlooks for the drug.
Financial analyst Jim Cramer discussed Eli Lilly's (LLY) potential dominance in the weight loss market and how Novo Nordisk (NVO) might face increased competition from it.
Eli Lilly (LLY) has announced its intention to acquire Centessa Pharmaceuticals in a deal valued at $7.8 billion.
Morgan Stanley has reaffirmed its 'Overweight' rating on Eli Lilly (LLY), highlighting the substantial growth potential of the company's new platform. This positive outlook is based on anticipated future developments.
Multiple financial institutions have updated their price targets and ratings for various companies, reflecting new outlooks on their performance and market conditions.
Eli Lilly (LLY) has announced the expansion of its pharmaceutical pipeline, driven by positive trial data and a new licensing agreement.
Jim Cramer shares his insights on Eli Lilly (LLY) and the growing market for weight loss drugs.